'Line treatment' diaporamas de présentation

Dr Maria Sofia Rosati Specialista in Oncologia Dottoranda in Medicina Molecolare

Ruolo delle antracicline convenzionali e liposomiali nel rechallange di I linea del MBC; wALT trial ( fase I-II). Dr Maria Sofia Rosati Specialista in Oncologia Dottoranda in Medicina Molecolare ROMA, 12 Novembre 2008. MBC: chi è la paziente in I linea?.

1.15k views • 96 slides

Current Opinion in the Colorectal Cancer Treatment

1k views • 81 slides

Post G.I. ASCO Update: Colorectal Cancer

Post G.I. ASCO Update: Colorectal Cancer. Ronald Burkes, M.D. Disclosure of Potential Conflicts of Interest. Honoraria:. Amgen Inc., Eli Lilly and Company, Hoffmann-La Roche, AstraZeneca, Sanofi-Aventis. Speaker:. Amgen Inc., Eli Lilly and Company, Hoffmann-La Roche, AstraZeneca.

798 views • 66 slides

First-Line Treatment for MM Patients

First-Line Treatment for MM Patients. Ruben Niesvizky Department of Medicine, Division of Hematology/Oncology, Weill-Cornell Medical College / New York Presbyterian Hospital, New York, NY, USA. Myelomacenter.org run9001@med.cornell.edu. Disclosures.

523 views • 38 slides

Hong-Hu Zhu, De-Pei Wu, Jie Jin, Jian-Yong Li, Jun Ma,

Oral tetra-arsenic tetra-sulphide formula achieved similar efficacy and safety compared to intravenous arsenic trioxide as first-line treatment of APL (multi-center randomized controlled trial APL07). Hong-Hu Zhu, De-Pei Wu, Jie Jin, Jian-Yong Li, Jun Ma,

465 views • 23 slides

310 views • 22 slides

Integrating Research and Clinical Practice

Integrating Research and Clinical Practice. Jim Koeller, M.S. Professor University of Texas at Austin & the Health Science Center, San Antonio, USA. Learning Objectives. Describe how research impacts clinical practice List 3 different types of clinical research

420 views • 19 slides

Swiss Group for Clinical Cancer Reseach

Bevacizumab continuation versus no continuation after first-line chemo - bevacizumab therapy in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial.

361 views • 19 slides

Pharmacological management of neuropathic pain

Pharmacological management of neuropathic pain . Imran Afzal ST1 Manorlands . Presentation Layout. MCQs Why read summary of NICE guidance

501 views • 17 slides

Current second-line treatment

Clinical development programme for Second-Line treatment Anton Pozniak World AIDS Conference, July 2014. Current second-line treatment. WHO standard: 2 new NRTIs plus LPV/r or ATV/r Efficacy of LPV/r + 2NRTIs in EARNEST and SECOND-LINE studies ? Use PI/r with Integrase Issues:

334 views • 17 slides

Infusional 5-FU/FA plus Oxaliplatin (FUFOX) vs. Capecitabine plus Oxaliplatin (CAPOX)

Tobias Arkenau. Infusional 5-FU/FA plus Oxaliplatin (FUFOX) vs. Capecitabine plus Oxaliplatin (CAPOX) as first-line treatment for metastatic colorectal cancer: safety and efficacy analysis from a phase III trial of the German AIO. Rationale for CAPOX in 1st-line ACRC.

300 views • 16 slides

The WHO 2013 ARV Consolidated Guidelines

The WHO 2013 ARV Consolidated Guidelines. Global policy, local disconnects. Sylvere Bukiki, ITPC West Africa AIDS2014. Context. One year after the launch of the Guidelines, ITPC investigated the reality on the ground for people living with HIV

318 views • 14 slides

No interests of conflict The study is notified to the Danish Data Protection Agency

272 views • 14 slides

Scabies

Ambash Riaz 12-10478 . Scabies. INTRODUCTION . caused by a mite named Sarcoptes scabiei cause a rash on humans dig under the outer layer of skin. Sarcoptes scabiei. Eight leg parasite 1/3 millimeter long Female = 0.3 mm-0.4 mm long Male = half of female size. Sarcoptes scabiei.

534 views • 10 slides

Resource requirements for reaching the treatment goals under PEPFAR

190 views • 10 slides

Hanfstein B et al. Leukemia 2012;[Epub ahead of print].

Early Molecular and Cytogenic Response Is Predictive for Long-Term Progression-Free and Overall Survival in Chronic Myeloid Leukemia (CML). Hanfstein B et al. Leukemia 2012;[Epub ahead of print]. Hanfstein B et al. Proc ASH 2011;Abstract 783. Background.

201 views • 9 slides

Access to ARVs in low and middle income countries -

250 views • 9 slides

Multiple Indicator Cluster Surveys Survey Design Workshop

Multiple Indicator Cluster Surveys Survey Design Workshop. Questionnaire for Children Under Five: Malaria. Global goals and targets. MDG 6: Combat HIV/AIDS, malaria and other diseases Target 6.C By 2015 have halted and begun to reverse the incidence of malaria and other major diseases

192 views • 8 slides

CLL Trials Newsletter ADMIRE, ARCTIC, CLL207, COSMIC, CLL201, CHOP-OR, RIAltO, CLL210 and RESPeCT

CLL Trials Newsletter ADMIRE, ARCTIC, CLL207, COSMIC, CLL201, CHOP-OR, RIAltO, CLL210 and RESPeCT. May 2011. Trials open to recruitment. ARCTIC CI: Professor Peter Hillmen

166 views • 4 slides

ECCO 15 and ESMO 34 Sep 20-24, 2009

ECCO 15 and ESMO 34 Sep 20-24, 2009. OMIT Bretagne /Pays de la Loire. Management of unresectable metastatic colorectal cancer (MCRC) in the real world with successive regimens with targeted therapies (bevacizumab and cetuximab) : the experience of the OMIT Bretagne Pays de la Loire.

172 views • 1 slides